Shopping Cart 0
Cart Subtotal
USD 0

NBE-Therapeutics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

NBE-Therapeutics AG (NBE-Therapeutics) is a biotechnology company that focuses on the development of antibody drug conjugates (ADC) to improve the treatment of cancer. ADCs act against cancer cells via tumor-specific antibodies and deliver powerful cellular toxins to such cancer cells. The company develops its product candidates harnessing its proprietary technology platforms, namely, Transpo-mAb display, an in vitro mammalian cell based expression and screening technology; sortase-enzyme mediated antibody conjugation (SMAC-technology); and anthracycline-based toxin platform. It has pipeline products for the treatment of pancreatic cancer, multiple myeloma, renal cell carcinoma and Hodgkin's lymphoma and other indications. The company has collaboration with various national and international academic institutions, to develop its ADC program candidates. NBE-Therapeutics is headquartered in Basel, Switzerland.

NBE-Therapeutics AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NBE-Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

NBE Therapeutics Raises Additional USD20.1 Million in Series B Financing 10

NBE Therapeutics Raises USD20.5 Million in Series B Financing 11

NBE Therapeutics Raises USD3.2 Million in Series A Financing 12

NBE Therapeutics Raises Fund through Seed Financing 13

Partnerships 14

NBE Therapeutics Enters into Co-Development Agreement with SOTIO 14

NBE-Therapeutics AG-Key Competitors 15

NBE-Therapeutics AG-Key Employees 16

NBE-Therapeutics AG-Locations And Subsidiaries 17

Head Office 17

Recent Developments 18

Corporate Communications 18

Nov 28, 2017: NBE-Therapeutics Appoints Dr. Nicole Onetto to Its Board of Directors 18

Apr 04, 2017: NBE-Therapeutics expands Board by Appointment of Hans-Peter Gerber 19

Appendix 20

Methodology 20

About GlobalData 20

Contact Us 20

Disclaimer 20


List Of Figure

List of Figures

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Key Facts 2

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NBE-Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NBE-Therapeutics AG, Deals By Therapy Area, 2012 to YTD 2018 8

NBE-Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

NBE Therapeutics Raises Additional USD20.1 Million in Series B Financing 10

NBE Therapeutics Raises USD20.5 Million in Series B Financing 11

NBE Therapeutics Raises USD3.2 Million in Series A Financing 12

NBE Therapeutics Raises Fund through Seed Financing 13

NBE Therapeutics Enters into Co-Development Agreement with SOTIO 14

NBE-Therapeutics AG, Key Competitors 15

NBE-Therapeutics AG, Key Employees 16

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

NBE-Therapeutics AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.